StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Saturday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday, March 21st. Guggenheim decreased their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Finally, Scotiabank cut their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP stock opened at $0.20 on Friday. The stock has a market cap of $50.41 million, a PE ratio of -0.90 and a beta of 2.52. The stock has a 50-day moving average of $0.50 and a 200-day moving average of $0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.55.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. As a group, sell-side analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several large investors have recently made changes to their positions in the stock. Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics in the fourth quarter valued at $7,992,000. Two Sigma Investments LP raised its stake in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 19,146 shares during the period. Two Sigma Advisers LP lifted its position in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 152,780 shares during the period. Finally, Long Focus Capital Management LLC increased its holdings in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.